-
Mashup Score: 12Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628 - 1 month(s) ago
Abstract. ATM inhibitors are being developed as radiosensitizers to improve the antitumor effects of radiotherapy, but ATM inhibition can also radiosensitize normal tissues. Therefore, understanding the elevated risk for normal tissue toxicities is critical for radiosensitizer development. This study focused on modeling the relationship between acute mucosal toxicity, radiation dose, fractionation schedule, and radiosensitizer exposure. The ATM inhibitor WSD0628 was combined with single or fractionated doses of radiation delivered to the oral cavity or esophagus of FVB mice. The potentiation by WSD0628 was quantified by a sensitizer enhancement ratio (SER), which describes the changes in radiation tolerance for radiation combined with WSD0628 relative to radiation-only regimens. WSD0628 profoundly enhanced radiation-induced acute oral and esophageal toxicities. For oral mucosal toxicity, the enhancement by WSD0628 with 3 fractions of radiation resulted in an SER ranging from 1.3 (0.25
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer - 1 month(s) ago
Local failure rates after treatment for locally advanced non–small cell lung cancer (NSCLC) remain high. Efforts to improve local control with a uniform dose escalation or dose escalation to midtreatment positron emission tomography (PET)-avid residual disease have been limited by heightened toxicity. This trial aimed to refine response-based adaptive radiation therapy (RT) and minimize toxicity by incorporating fluorodeoxyglucose-PET (FDG-PET) and ventilation-perfusion single-photon emission computed tomography (SPECT) imaging midtreatment.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
📢Out in @IJROBP: Small phase II with promise of improved outcomes with PET guided, dose escalated #radiotherapy in locally advanced #lungcancer We await NARLA-2 results also showing improved local control with similar approach! #lcsm #radonc https://t.co/xTgUcE3wwc
-
-
Mashup Score: 11DNA-PK inhibition shows differential radiosensitization in orthotopic GBM PDX models based on DDR pathway deficits - 2 month(s) ago
Abstract. Glioblastoma (GBM) remains one of the most therapy-resistant malignancies with frequent local failures despite aggressive surgery, chemotherapy, and ionizing radiation (IR). Small molecule inhibitors of DNA-dependent protein kinase (DNA-PKi’s) are potent radiosensitizers currently in clinical trials. Determining which patients may benefit from radiosensitization with DNA-PKi’s is critical to avoid unnecessary increased risk of normal tissue toxicity. In this study we used GBM patient derived xenografts (PDXs) in orthotopic murine models to study the relationship between molecular features, pharmacokinetics, and the radiosensitizing potential of the DNA-PKi peposertib. We show that peposertib radiosensitizes established and PDX GBM lines in vitro at 300nM and above, with significant increase in radiosensitization by maintaining post-IR exposure for >12 hours. Radiosensitization by peposertib is mediated by catalytic inhibition of DNA-PK, and knock-down of DNA-PK by short hairp
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
⚠️Important data from @MayoRadOnc (@theNCI U01) that even a DNA-PKi can have variable radiosensitizing effects in vivo, here for GBM models‼️ TP53 mutant status may be important🤔 @DKirschMDPhD @guptalabunc @xrtGenomics @StevenLin_MDPhD @AmyWisdom8 https://t.co/zp86iWsxSi
-
-
Mashup Score: 25The Society of Thoracic Surgeons Expert Consensus on the Multidisciplinary Management and Resectability of Locally Advanced Non-Small Cell Lung Cancer - 2 month(s) ago
The contemporary management and resectability of locally advanced lung cancer are undergoing significant changes as new data emerge regarding immunotherapy and targeted treatments. The objective of this document is to review the literature and present consensus among a group of multidisciplinary experts to guide the determination of resectability and management of locally advanced non-small cell lung cancer (NSCLC) in the context of contemporary evidence.
Source: www.annalsthoracicsurgery.orgCategories: General Medicine News, Hem/OncsTweet-
MultiD management of locally advanced NSCLC: Rapidly moving, complex + exciting area🔥 ➡️Honor/privilege to work on @STS_CTsurgery recs🙏 ➡️Appreciate inclusion of #medonc #radonc 👍 @biniamkidaneMD @theabzlab @JoelNealMD @BrendonStilesMD @JustinGainor https://t.co/HbIIIhJvXH
-
-
Mashup Score: 10JBL Symposium - 2 month(s) ago
JBL Symposium XXVII – 2024 Friday, October 11th, 2024 Harvard T. H. Chan School of Public Health 1:00 PM – 5:00 PM, with reception and poster session immediately following Snyder Audito…
Source: www.hsph.harvard.eduCategories: General Medicine News, Hem/OncsTweet-
Terrific program tomorrow at the in-person only @HarvardChanSPH JBL Symposium🔥 Featuring @DemariaLab_WCM @DrRebeccaHowel1 @HugoAerts (and no, speakers did not get selected based on whether there are (still) on #Twitter or not😉) be there or be 🟧😅 ⚠️https://t.co/3nmRRY4HKA… https://t.co/Wat20YKLme https://t.co/rL3USdQjMy
-
-
Mashup Score: 10JBL Symposium - 2 month(s) ago
JBL Symposium XXVII – 2024 Friday, October 11th, 2024 Harvard T. H. Chan School of Public Health 1:00 PM – 5:00 PM, with reception and poster session immediately following Snyder Audito…
Source: www.hsph.harvard.eduCategories: General Medicine News, Hem/OncsTweet-
Terrific program tomorrow at the in-person only @HarvardChanSPH JBL Symposium🔥 Featuring @DemariaLab_WCM @DrRebeccaHowel1 @HugoAerts (and no, speakers did not get selected based on whether there are (still) on #Twitter or not😉) be there or be 🟧😅 ⚠️https://t.co/3nmRRY4HKA… https://t.co/Wat20YKLme https://t.co/rL3USdQjMy
-
-
Mashup Score: 32
PURPOSENRG-RTOG0617 demonstrated a detrimental effect of uniform high-dose radiation in stage III non–small cell lung cancer. NRG-RTOG1106/ECOG-ACRIN6697 (ClinicalTrials.gov identifier: NCT01507428), a randomized phase II trial, studied whether …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Another study where #radiotherapy dose escalation (PET guided 71 Gy vs 60 Gy) did not improve outcomes🤔 Disappointing Sample size feels small to find dose response IMO 2-yr local control of 55-60% clearly highlights need for treatment intensification⚠️ https://t.co/oEdglmcVsq
-
-
Mashup Score: 28
Mark your calendar now to attend the 66th ASTRO Annual Meeting, being held in the nation’s capital, Washington, DC, September 29 – October 2, 2024! The
Source: www.symplur.comCategories: General Medicine News, Hem/OncsTweet-
Symplur back up😊 👀Final look at this past week of #ASTRO24 🔥🔥 Noticeable GU dominance ‼️😇 👏👏👏 everyone🙏 See you at #ASTRO25🫡 @sueyom @SameerKeoleMD @NehaVapiwala ➡️https://t.co/ZvomELPhLA https://t.co/fQDsvmRd2a https://t.co/FWj2OFm6Yb
-
-
Mashup Score: 19Irradiation with Carbon Ions Effectively Counteracts Hypoxia-related Radioresistance in a Rat Prostate Carcinoma - 3 month(s) ago
Hypoxia in tumors is associated with increased malignancy and resistance to conventional photon radiation therapy. This study investigated the potential of particle therapy to counteract radioresistance in syngeneic rat prostate carcinoma.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
👨🏫We do teach that high-LET #radiotherapy can overcome tumor hypoxia 📢Now finally some clinically relevant data in #ProstateCancer🔥 #radbio @lauremarignol @_MichaelBaumann @sophia_kamran @drjefstathiou @DeborahCitrin @BrianMarples FREE PDF‼️ https://t.co/hiheiTlk63
-
-
Mashup Score: 23The Effect of Radiation Treatment of Solid Tumors on Neutrophil Infiltration and Function: A Systematic Review - 3 month(s) ago
Radiation therapy (RT) initiates a local and systemic immune response which can induce antitumor immunity and improve immunotherapy efficacy. Neutrophils are among the first immune cells that infiltrate tumors after RT and are suggested to be essential for the initial antitumor immune response. However, neutrophils in tumors are associated with poor outcomes and RT-induced neutrophil infiltration could also change the composition of the tumor microenvironment (TME) in favor of tumor progression.
Source: www.redjournal.orgCategories: General Medicine News, Hem/OncsTweet-
📢Super timely and important #radbio review in the #RedJournal: Effect of #radiotherapy on neutrophils‼️ @sueyom @CVanpouilleBox @AmyWisdom8 @JulieSchwarz14 @DKirschMDPhD @CGrassberger FREE PDF⚠️ https://t.co/BNNFEXFEu4
-
Nicely done mouse study by @MayoRadOnc on the radiobiology of combining a DDR inhibitor with #radiotherapy👍 @mct_aacr @DKirschMDPhD @xrtGenomics Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628 https://t.co/EdfNpDVZKV